



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2199844 C 2007/04/10

(11)(21) **2 199 844**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1995/09/13
(87) Date publication PCT/PCT Publication Date: 1996/03/21
(45) Date de délivrance/Issue Date: 2007/04/10
(85) Entrée phase nationale/National Entry: 1997/03/12
(86) N° demande PCT/PCT Application No.: US 1995/011678
(87) N° publication PCT/PCT Publication No.: 1996/008248
(30) Priorité/Priority: 1994/09/13 (IL110943)

(51) Cl.Int./Int.Cl. **A61K 31/35** (2006.01),
A61K 31/366 (2006.01)
(72) Inventeurs/Inventors:
SAVION, NAPHTALI, IL;
BRENNER, SARA, IL
(73) Propriétaire/Owner:
RAMOT AT TEL-AVIV UNIVERSITY LTD., IL
(74) Agent: SMART & BIGGAR

(54) Titre : COMPOSITION POUR LE TRAITEMENT D'AFFECTIONS DE LA PEAU
(54) Title: COMPOSITIONS FOR THE TREATMENT OF SKIN DISORDERS

(57) **Abrégé/Abstract:**

An inhibitor of cholesterol synthesis is used for the treatment, alleviation or prevention of skin disorders.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/35 02199844		A1	(11) International Publication Number: WO 96/08248
			(43) International Publication Date: 21 March 1996 (21.03.96)
(21) International Application Number: PCT/US95/11678 (22) International Filing Date: 13 September 1995 (13.09.95) (30) Priority Data: 110943 13 September 1994 (13.09.94) IL (71) Applicant (for all designated States except US): RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. [IL/IL]; 32 Haim Levanon Street, 69975 Ramat Aviv (IL). (71) Applicant (for MW only): SHOSHAN, Herbert, Z. [US/IL]; 344 Azur, Makabim (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): SAVION, Naphtali [IL/IL]; 9/16 Oranim Street, 54052 Givat Shmuel (IL). BRENNER, Sara [IL/US]; 36 Etzel Street, Herzlia-Pituach (IL). (74) Agent: COHEN, Herbert; Wigman, Cohen, Leitner & Myers, P.C., Crystal Square 3, Suite 200, 1735 Jefferson Davis Highway, Arlington, VA 22202 (US).			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITIONS FOR THE TREATMENT OF SKIN DISORDERS			
(57) Abstract An inhibitor of cholesterol synthesis is used for the treatment, alleviation or prevention of skin disorders.			

0 2 1 9 9 8 4 4

COMPOSITIONS FOR THE TREATMENT OF SKIN DISORDERS

FIELD OF THE INVENTION

The present invention is generally in the field of compositions for topical application onto the skin intended to improve the skin's condition. The present invention provides method and compositions useful for
5 improving various skin conditions, in particular acne.

BACKGROUND OF THE INVENTION

Acne is a chronic inflammatory disorder of the pilosebaceous follicles, particularly in the face and neck region, occurring most commonly
10 in adolescence between the ages of about 14 to about 19. Acne involves increased sebum secretion, hyperkeratinization in the infundibulum of the follicular duct, increased microbial colonization and inflammation (Strauss, J.S., *J. Dermatol. Treat.*, 1:3-6 (1989)). Various methods for the treatment of acne and other sebaceous glands' inflammation have been
15 proposed, ranging from special diets, prevention of contact of the skin by known acneogenic agents (e.g., low grade cosmetics), use of endocrine preparations containing progesterone or estrogen, and others, most of which have not proved to be effective. Additionally, it has also been proposed to use antiseptic, antibacterial and wide-spectrum antibiotic compounds in both
20 topical and systemic application.

All hitherto used anti-acne agents were effective in suppressing the development of microbial population, keratinization and comedo formation in the sebaceous glands. However, only few of the anti-acne agents hitherto used were effective in the reduction of the sebum excretion rate (Gollnick, H., *J. Dermatol. Treat.* 1:S23-S28 (1990) and none of the agents was useful in affecting lipid biosynthesis in the pilosebaceous unit.

Isoprenoid groups such as cholesterol, squalene and cholesteryl-esters are synthesized via the mevalonate pathway (Goldstein, J.L., Brown, M.S., *Nature*, 34B, 425 (1990)), wherein the end-product is cholesterol. One of the key enzymes which regulate the production of mevalonate, the precursor of the above isoprenoid groups, is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Inhibitors of this enzyme inhibit the synthesis of cholesterol and are thus used as antihypercholesterolemic medicaments for the treatment of arteriosclerosis, hyperlipemia and related diseases. An example of such an inhibitor is Lovastatin (Merck Index 5460, U.S. 4,231,938). Pharmaceutical compositions comprising this inhibitor of HMC-CoA reductase are given orally or parenterally to patients suffering from arteriosclerosis or hyperlipemia.

20 SUMMARY OF THE INVENTION

In accordance with the invention it has surprisingly been found that acne can be treated by the use of a topically applied inhibitor of cholesterol synthesis. In accordance with the invention use is thus made with an inhibitor of cholesterol synthesis to treat various skin disorders.

25 In accordance with the present invention there is thus provided a composition for topical skin application comprising a carrier and, as an active ingredient, an effective amount of an inhibitor of cholesterol synthesis.

PCT/US 95/11678
IPEA/CC 17 JAN 1997 5

-3-

The composition of the invention may be a pharmaceutical or cosmetic composition.

The pharmaceutical composition of the invention may be used for various indications including acne vulgaris, psoriasis, scalp dandruff and seborrhea.

5 The present invention further concerns the use of inhibitors of cholesterol synthesis, for example, inhibitors of the HMG-CoA reductase, for the preparation of topical pharmaceutical compositions for the treatment, alleviation or prevention of skin disorders.

Also provided by the invention is a method for improvement of skin
10 condition comprising topically applying into the skin a composition comprising a carrier and, as an active ingredient, an effective amount of an inhibitor of cholesterol synthesis. A particular application of the method is the treatment, alleviation or prevention of acne.

The term "*effective amount*" should be understood as meaning an amount of
15 an active ingredient needed to achieve a desired therapeutic or pharmaceutical effect. For example, in a pharmaceutical composition of the invention an effective amount of an inhibitor of cholesterol synthesis is an amount which is sufficient, in the administration regimen of the pharmaceutical composition in the framework of treatment, to achieve an improvement in the skin's condition.

20 Inhibitors of cholesterol synthesis useful in accordance with the present invention are various agents which inhibit the production of the end product, i.e., cholesterol, or any of the intermediates of the various steps of the mevalonate pathway in which cholesterol is produced from the precursors acety CoA and acetoacetyl CoA. The inhibitors can be agents which inhibit the enzymes involved
25 in the various steps or agents which serve as sequesters of the intermediates, both of which reduce the amount of cholesterol produced in this process.

72844-75

-3a-

According to one aspect of the present invention, there is provided a composition for topical skin application comprising a carrier and, as sole active ingredient, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

According to another aspect of the present invention, there is provided a pharmaceutical composition as described herein for the treatment of acne.

According to still another aspect of the present invention, there is provided a pharmaceutical composition as described herein for the treatment of scalp dandruff.

According to yet another aspect of the present invention, there is provided a pharmaceutical composition as described herein for the treatment of seborrhea.

According to yet a further aspect of the present invention, there is provided use of an inhibitor of 3-hydroxy-3-methylglutary coenzyme A (HMG-CoA) reductase (HMG-CoA reductase) for the preparation of a topical pharmaceutical composition for the treatment, alleviation or prevention of skin disorders.

72844-75

- 4 -

In accordance with a preferred embodiment of the invention, the inhibitor of cholesterol synthesis is an agent which inhibits the HMG-CoA reductase, such as Lovastatin.

5 The concentration of the Lovastatin is preferably about 0.2 - 10% and most preferably about 2%.

 The inhibitor of cholesterol synthesis may be applied to the skin with various other agents such as, antimicrobial agents, e.g. antibiotics, for the treatment or
10 prevention of a secondary infection, a skin peeling agent, retin-A separately or together with resorcinol, etc.

 The carrier of the composition of the present invention may be any pharmaceutically or cosmetically acceptable carrier such as, for example, ethanol, gel,
15 liposome formulation, ointment, salve, etc.

 The pharmaceutical composition of the present invention may be sold in a commercial package comprising the composition and printed matter providing instructions for use thereof in treating a condition set out in the
20 instructions.

EXAMPLES:

I. Preparation of the Composition

 Lovastatin capsules (Mevacor™, Merck, U.S.A.) were ground and the active ingredient was separated from the
25 excipient by extraction with ethanol 95% and filtration to yield a 2% solution of Lovastatin in ethanol.

II. Clinical Trials

 The efficacy of the above preparation was tested in two separate clinical trials.

72844-75

- 4a -

A. Trial I

Pharmaceutical compositions prepared as described above were topically applied twice daily for a period of 12 weeks, to the faces of two individuals suffering from 5 acne vulgaris. The patients were required to discontinue all other topical and systemic anti-acne treatment 30 days prior

to the beginning of the trial and discontinued all facial and cosmetic treatment seven days prior to the onset of treatment.

5 The acne condition was assessed by recording all acne lesions including inflamed acne lesions (papules and pustules) and non-inflamed acne lesions, (white and black comedos) prior to the beginning of treatment and 4, 8 and 12 weeks following the onset of treatment.

10 In both patients, improvement in all mentioned lesions was noticed and at the end of the 12 week treatment period the number of lesions decreased to less than half. No side effects were noticed save for a mild dryness of the skin, which is likely a result of the ethanol.

B. Trial II

15 4 patients, 16-25 years of age, consisting of 2 males and 2 females, having mild to moderate acne were treated with the above preparation. All medications and cosmetics were stopped for 14 days, following which the patients were asked to apply the preparation twice daily for 8 weeks and to refrain from using all other forms of treatment and cosmetics during treatment. Prior to and after 4 and 8 weeks of treatment, the number of acne lesions (papules, pustules and white and black comedos) was recorded, and the results, shown in the following Table 1 demonstrated an improvement in all 4 patients evidenced by reduction of the number of all types of lesions:

0 2 1 9 9 8 4 4

Table 1

Number of acne lesions before and during treatment

5	Patient	Lesions	Before Treatment	After 1 month	After 2 months
	1	Pustules Papules White & blackheads	10 11 18	7 3 10	3 2 7
	2	Pustules Papules White & blackheads	17 17 18	15 15 15	2 10 6
	3	Pustules Papules White & blackheads	7 12 22	2 7 14	- 4 7
	4	Pustules Papules White & blackheads	20 16 15	18 9 10	5 5 5
10	Average	Pustules Papules White & blackheads	13 14 18	10 8 12	2 5 6

72844-75

- 7 -

CLAIMS:

1. A composition for topical skin application for the treatment, alleviation or prevention of acne, comprising a carrier and, as sole active ingredient, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase of statin type.
2. The composition according to claim 1, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.
- 10 3. The pharmaceutical composition according to claim 2, wherein the inhibitor is Lovastatin.
4. The pharmaceutical composition according to claim 3, wherein the concentration of the Lovastatin is about 0.2-10%, weight/volume.
- 15 5. The pharmaceutical composition according to claim 3, wherein the concentration of the Lovastatin is about 2%, weight/volume.
6. Use of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase of statin type in preparation
20 of a topical pharmaceutical composition for treatment, alleviation or prevention of acne.
7. The use according to claim 6, wherein the inhibitor is Lovastatin.
8. Use of an inhibitor of 3-hydroxy-3-methylglutaryl
25 coenzyme A (HMG-CoA) reductase of statin type for treatment, alleviation or prevention of acne.
9. The use according to claim 8, wherein the inhibitor is Lovastatin.

72844-75

- 8 -

10. A commercial package comprising the composition of any one of claims 1 to 5, and instructions for the use thereof in treating acne.

SMART & BIGGAR
OTTAWA, CANADA

PATENT AGENTS